Insider Shareholders with Direct Ownership of Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
This section provides a comprehensive overview of the insiders with direct ownership of Biohaven Pharmaceutical Holding CO Ltd. (BHVN). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Biohaven Pharmaceutical Holding Co Ltd. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 559,000 | 62,265 | 870,648 $43.3 Million | 3 |
Nov 29, 2021
Reduced 1.3%
|
|
|
Vlad Coric
Chief Executive Officer |
56,900 | 118,380 | 830,891 $41.3 Million | 11 |
Oct 03, 2022
Reduced 9.97%
|
|
John Tilton
Chief Commercial Officer |
5,875 | 7,425 | 1,614 $80,312 | 11 |
Oct 03, 2022
Reduced 75.85%
|
| 0 | 2,900 | 0 $0 | 1 |
Oct 03, 2022
Reduced 100.0%
|
|
| 38,000 | 2,633,658 | 0 $0 | 7 |
Oct 03, 2022
Reduced 100.0%
|
|
|
George C. Clark
VP, Chief Accounting Officer |
17,710 | 23,495 | 0 $0 | 15 |
Oct 03, 2022
Reduced 100.0%
|
| 1,875 | 10,640 | 0 $0 | 2 |
Oct 03, 2022
Reduced 100.0%
|
|
| 12,000 | 12,000 | 0 $0 | 2 |
Dec 20, 2021
Reduced 100.0%
|
|
| 513,063 | 3,025,001 | 0 $0 | 7 |
Oct 03, 2022
Reduced 100.0%
|
|
|
Elyse Stock
Chief Medical Officer |
46,358 | 48,202 | 0 $0 | 15 |
Oct 03, 2022
Reduced 100.0%
|
|
Matthew Buten
Chief Financial Officer |
12,500 | 12,500 | 0 $0 | 3 |
Oct 03, 2022
Reduced 100.0%
|
|
Charles Conway
Chief Scientific Officer |
24,385 | 27,270 | 0 $0 | 9 |
Oct 03, 2022
Reduced 100.0%
|
|
Kimberly Gentile
SVP, Clinical Operations |
38,500 | 42,139 | 0 $0 | 11 |
Oct 03, 2022
Reduced 100.0%
|
|
James Engelhart
Strategic Advisor |
53,150 | 58,851 | 0 $0 | 13 |
Oct 03, 2022
Reduced 100.0%
|
|
William A Jones Jr
CCO-Migraine & Common Disease |
49,750 | 52,761 | 0 $0 | 13 |
Oct 03, 2022
Reduced 100.0%
|